Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document a foreign private issuer with ordinary shares and listed warrants, using Form 6-K reports to disclose material events, Nasdaq listing-compliance notices, capital actions, securities purchase agreements and warrant matters. The filings include disclosures on a board-approved reverse stock split, adjustments to warrant terms, a registered ordinary-share offering under a Form F-3 shelf registration statement, and the repurchase and cancellation of a warrant.
EUDA's regulatory reports also describe its healthcare activities in Asia, including a non-exclusive arrangement to market selected Shenzhen Inno immunotherapies to customers in Malaysia through CK Health Plus Sdn Bhd, with treatments conducted in China.
EUDA Health Holdings Limited, a foreign private issuer based in Singapore, submitted a Form 6-K for September 2025. The company reports an “Other Events” item and furnished a press release dated September 10, 2025, as Exhibit 99.1.
The report is signed by Interim Chief Financial Officer Vivian Tay on behalf of the company.
EUDA Health Holdings Limited submitted a Form 6-K as a foreign private issuer to furnish a company press release as an exhibit. The report is categorized as an "Other Events" update and is tied to a press release dated September 4, 2025.
The filing is signed on behalf of the company by Interim Chief Financial Officer Vivian Tay, indicating management’s authorization of this disclosure under the Securities Exchange Act of 1934.
EUDA Health Holdings Limited amended a prior report to provide legal support for a previously disclosed financing. The company had entered into a convertible promissory note purchase agreement dated August 1, 2025 with an institutional investor for Notes in an aggregate amount not to exceed $10,000,000. Ordinary shares issuable upon conversion of these Notes will be issued under a prospectus supplement to the company’s Form F-3 registration statement. This amendment files an opinion of counsel and related consent covering the validity of those shares.
EUDA Health Holdings Ltd. (Nasdaq: EUDA) has filed a Form 424(b)(5) prospectus supplement to register up to 5,000,000 ordinary shares underlying a US$10 million one-year convertible note to be sold to Indigo Capital LP in a registered-direct transaction. Notes are issued at a 10 % original-issue discount (net cash ≈ US$9 million; estimated net proceeds after expenses ≈ US$8.98 million) and convert at 85 % of the share’s Nasdaq close on the conversion date, capped at 4.99 % beneficial ownership. A 5-day closing bid below US$2.00 constitutes an “Early Default,” accelerating repayment or conversion; no interest accrues. No public market will exist for the notes.
The financing adds to an already highly dilutive capital structure: 37.16 million shares outstanding, 8.9 million warrants and other convertibles. FY-2024 results showed a US$15.4 million net loss, US$3.4 million working-capital deficit and only US$0.2 million cash. The auditor issued a going-concern warning and management cited material-control weaknesses. Proceeds are earmarked for working capital, M&A and general corporate purposes.
EUDA is pivoting from low-demand medical clinics to wellness services after acquiring CK Health (2.2 % of 2024 revenue) and partnering for stem-cell packages. Two large shareholders control ~53 % of equity, and resale registration rights could pressure the stock. Investors face execution, dilution, and delisting risks offset by near-term liquidity from the note.